NFX Bio
VC Fund
San Francisco, United States
NFX Bio is a fund initiative that seeks to invest in scientist-founders at the seed stage with a technology platform approach.Led by Omri Amirav Drory, a venture partner with NFX, who founded Genome Compiler, it helps scientists learn to be founders and guides biology companies with information technology to be a critical distinction with massiveimplications.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries NFX Bio invests in
Stages NFX Bio invests in
Countries NFX Bio invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $7M–$22M
Investment Focus
Industry
- Therapeutics 4 (67%)
- Biotechnology 3 (50%)
- Medical 2 (33%)
- Health Care 2 (33%)
- Pet 1 (17%)
Stage
- Seed 5 (83%)
- Series B 1 (17%)
Country
- United States 4 (67%)
- Israel 2 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Emily Leproust
Investment Committee
|
Investment Committee | Total investments: 3 | Find email | |
Gigi Levy Weiss
Investment Committee
|
Investment Committee | Total investments: 191 | Find email | |
Gita Reinitz
Principal
|
Principal | Total investments: 0 | Find email | |
James Currier
Investment Committee
|
Investment Committee | Total investments: 147 | Find email | |
Omri Amirav-Drory
Venture Partner
|
Venture Partner | Total investments: 17 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Radar Therapeutics pioneer in treatment modality, precision-expressed mRNA-based therapeutics. | $13.4M / Seed / May 23, 2024 | ||
| Eleven Therapeutics is a research firm that unleashes the power of RNAi technology that helps to create precise and durable therapeutics. | $22M / Seed / Aug 02, 2022 | ||
| Solving cancer resistance. | $12M / Seed / Jul 04, 2022 | ||
| Pangea provides services to Pharma/Biotech companies based on its proprietary platform. | $7M / Seed / Jul 07, 2021 | ||
| C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations.The cancer intelligence company is developing a platform that can perform whole-genome sequencing using only 2 milliliters of blood. Its ultra-sensitive liquid biopsy assay allows physicians to monitor patient treatment response and detecttreatment failure or disease recurrence months and potentially years earlier than current monitoring methods. C2i’s cancer diagnostics service uses artificial intelligence pattern recognition and the whole-genome analysis to spot trace amounts of cancer much quicker, in about a week, to inform better treatment decisions and ultimately save lives. The company aims to help patients avoid unnecessary overtreatment with toxic chemotherapy or radiation, as well as to prevent them from going without treatment while cancer quietly grows and metastasizes.In 2019, Boris Oklander, Asaf Zviran, and Ezra Sofer established the company in New York, New York. | $100M / Series B / Apr 15, 2021 | ||
| CleverPet is a hardware and software company that offers smart light and sound games for dogs. | $120K / Seed / Jun 05, 2015 |
Co-Investors
Casdin Capital
2 deals together
Pioneer Fund
2 deals together
Qualcomm Robotics Accelerator
2 deals together
Alexandria Real Estate Equities
1 deal together
Asimov Ventures
1 deal together
BEVC
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does NFX Bio invest in?
NFX Bio invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Seed and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does NFX Bio invest in?
NFX Bio typically joins rounds of $7M–$22M at Seed. These are whole funding-round sizes, not NFX Bio's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds NFX Bio took part in.
How do I contact NFX Bio?
Public channels for NFX Bio include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at NFX Bio?
The team at NFX Bio includes Emily Leproust (Investment Committee), Gigi Levy Weiss (Investment Committee) and Gita Reinitz (Principal). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
